A Randomized Controlled Trial of Cognitive Behavioral Group Therapy for Bipolar Disorder
A Randomized Controlled Trial of Cognitive Behavioral Group Therapy for Bipolar Disorder
复制标题
DOI：
10.1159/000320738
复制
发表时间：
2011-01-01
影响因子：
22.8
通讯作者：
Lafer, B.
中科院分区：
文献类型：
--
作者：
Gomes, B. C.;Abreu, L. N.;Lafer, B.
背景资料：本研究旨在评估连续性认知行为团体治疗（CBGT）预防双相情感障碍患者情感正常发作复发的有效性。研究方法：一项随机对照单盲试验，50例I型和II型双相情感障碍患者在门诊随访至少12个月，疾病缓解。开发了一个实验性CBGT手册，并将其添加到常规治疗（TAU）中，并将结果与单独TAU进行比较。结果如下：意向治疗分析显示，两组之间在直至任何复发的时间方面没有差异（Wilcoxon = 0.667; p = 0.414）。当考虑复发类型时，抑郁（Wilcoxon = 3.328; p = 0.068）或躁狂发作（Wilcoxon = 1.498; p = 0.221）仍然没有差异。虽然两组之间的发作发生率也没有差异（chi（2）= 0.28; p = 0.59），但与TAU相比，CBGT治疗患者的中位复发时间更长（Mann-Whitney = -2.554; p = 0.011）。结论：CBGT治疗组的复发时间和发作次数无差异。然而，TAU组的中位复发时间较短。更大样本的研究可能有助于澄清我们的CBGT方法是否可以预防双相情感障碍的新发作。我们的研究结果还表明，CBGT是可行的，在情感正常的双相情感障碍患者，并应在未来的研究进行调查。据我们所知，这是第一次出版的对照试验CBGT的心境正常的双相情感障碍患者。版权所有（C）2011 S. Karger AG，巴塞尔
Background: This study evaluated the effectiveness of adjunctive cognitive behavioral group therapy (CBGT) to prevent recurrence of episodes in euthymic patients with bipolar disorder. Methods: A randomized controlled single-blind trial was conducted with 50 patients with bipolar disorder types I and II followed up for at least 12 months in an outpatient service and whose disease was in remission. An experimental CBGT manual was developed and added to treatment as usual (TAU), and results were compared with TAU alone. Results: Intention-to-treat analysis showed that there was no difference between groups in terms of time until any relapse (Wilcoxon = 0.667; p = 0.414). When considering type of relapse, there was still no difference in either depressive (Wilcoxon = 3.328; p = 0.068) or manic episodes (Wilcoxon = 1.498; p = 0.221). Although occurrence of episodes also did not differ between groups (chi(2) = 0.28; p = 0.59), median time to relapse was longer for patients treated with CBGT compared to TAU (Mann-Whitney = -2.554; p = 0.011). Conclusions:Time to recurrence and number of episodes were not different in the group of patients treated with CBGT. However, median time to relapse was shorter in the TAU group. Studies with larger samples may help to clarify whether our CBGT approach prevents new episodes of bipolar disorder. Our findings also indicated that CBGT is feasible in euthymic patients with bipolar disorder and should be investigated in future studies. To our knowledge, this is the first publication of a controlled trial of CBGT for euthymic patients with bipolar disorder. Copyright (C) 2011 S. Karger AG, Basel